Tackling Urgent Antimicrobial Resistance Threats In Australia—in Action
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Antimicrobial resistance is a major global concern, there are limited new treatment options and current resistance surveillance practices have limitations. As a part of this fellowship I will collaborate with industry partners, utilise geographical mapping and novel DNA sequencing technologies with a view to enhance resistance surveillance for gonorrhoea and other public health threats, inform new treatment strategies and better understand the spread of gonorrhoea in the population.
Personalised Medicine Markers Of Anti-EGFR Antibody Therapy In Metastatic Colorectal Cancer: Accelerating Clinical Translation With Collaborative Meta-analyses Based On Individual-participant Data
Funder
National Health and Medical Research Council
Funding Amount
$300,953.00
Summary
When selecting cancer therapy we take into account ‘biomarkers’, biological cancer characteristics that predict treatment success. We will work with an international group, the Advanced Colorectal Cancer Database, to analyse individual patient clinical trial data. We intend to validate biomarkers used to select treatment with cetuximab or panitumumab. Cancer genes called KRAS, NRAS, PTEN, PIK3CA, EREG and BRAF will be examined. Our study will provide best evidence for personalised treatment.
Methods For Evaluating The Therapeutic Impact Of Diagnostic Tests - Development Of Guidelines
Funder
National Health and Medical Research Council
Funding Amount
$132,325.00
Summary
New diagnostic tests are frequently adopted in clinical practice without any evidence that they improve patient outcomes. This project will produce the first guidelines about the role and optimal design of studies assessing the impact of a new test on therapeutic decisions for conclusions about its clinical value. This work will inform researchers and clinicians to improve evidence-based diagnostic practice and promote the more efficient use of limited health care resources.
SFRP4 As A Novel Diagnostic And Therapeutic Target For Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$137,700.00
Summary
Gastric cancer is a common cancer with poor survival, but is and potentially curable when diagnosed at an early stage. However currently there are no non-invasive markers for the early detection of gastric cancer, and treatments for advanced cancer are limited. Secreted frizzled related protein 4 (SFRP4) is a protein that is thought to play a role in invasion of gastric cancer. This study will investigate the utility SFRP4 as a diagnostic test and possible therapeutic for gastric cancer.
Policy Translation Of An Australian Evaluation Of Computed Tomography (CT) Scanning
Funder
National Health and Medical Research Council
Funding Amount
$398,295.00
Summary
Our study will inform the national health care policy debate with respect to the future role of CT scanning in the health system, and provide the information needed to launch the dialogue among expert clinicians and technicians necessary for practitioner consensus in the appropriate methods for use of CT scanning. This study will use routinely collected administrative health data and data collected from CT scan providers in WA to evaluate the use of CT scanning in the Australian health system.
Mapping And Treating Early Clinical Stages Of Mental Disorders During Transition To Adulthood
Funder
National Health and Medical Research Council
Funding Amount
$863,413.00
Summary
The research proposed in this Fellowship is aimed at young people with emerging mental ill-health. The specific goals and targets are to formulate novel diagnoses that work; develop novel, personalised and safe psychosocial and biotherapies; and scale up well-evaluated 21st century models of mental health care.
Micropapillary Adenocarcinoma: The Emergence Of A Discrete Lung Cancer Phenotype And Its Genomic And Transcriptomic Characterization.
Funder
National Health and Medical Research Council
Funding Amount
$117,565.00
Summary
I believe I can describe a new subtype of lung cancer, which has never been classified by the World Health Organization. This has been previously mis-classified or simply ignored. My hypothesis is that this is a distinct disease by virtue of patterns of genetic abnormalities as well as features visible under the microscope. I also believe it is one of the most aggressive cancers and needs new treatments.